Day: November 2, 2022

On April 3, 2014, Wilson, Kevin J.; Witter, David J.; Daniels, Matthew H.; Angeles, Angie R.; Siliphaivanh, Phieng; Sloman, David; O’Boyle, Brendan; Falcone, Danielle; White, Catherine; Ferguson, Ron; Zhou, Wei; Lipford, Kathryn; Mansoor, Umar Faruk; Fevrier, Salem; Huang, Xianhai; Kurukulasuriya, Ravi; Richard, Judson E.; Tang, Shuyi; Boyce, Christopher; Kozlowski, Joseph; Bakshi, Raman Kumar; Karunakaran, Ganesh Babu published a patent.Electric Literature of 215610-30-3 The title of the patent was Preparation of pyrazolopyridinyl ureas as ERK inhibitors. And the patent contained the following:

The title compounds I [R1 = OR4, S(O)tR5; t = 0-2; R2 = H, alkyl; alkyl-O-alkyl, alkylaryl, etc.; R4 = alkyl-O-alkyl, alkylaryl, etc.; R5 = alkyl, alkyl-O-alkyl; R10, R11 = H, halo, alkyl, etc.] which are ERK inhibitors useful in treating cancer, were prepared E.g., a multi-step synthesis of (1R)-II, starting from Me 4,6-dichloropyridine-3-carboxylate and hydrazine, was described. Exemplified compounds I were tested in human ERK2 activity assay (data given). Pharmaceutical compositions comprising compound I, alone or in combination with an effective amount of at least one chemotherapeutic agent, were disclosed. The experimental process involved the reaction of 5-Methoxy-1H-pyrazole(cas: 215610-30-3).Electric Literature of 215610-30-3

The Article related to pyrazolopyridinyl urea preparation erk inhibitor antitumor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Electric Literature of 215610-30-3

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On September 7, 2021, Cho, Won Je published a patent.Name: 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde The title of the patent was Preparation of pyrazolecarboxamide for preventing or treating metabolic disease. And the patent contained the following:

The present invention relates to a novel pyrazolecarboxamide carboxamide compound I [R1 = H, 3-OMe, 3,4-(OMe)2, 4-Me; R2 = H, CF3, NH2; OR3 = meta-(3-pyridinyloxy), para-(4-isopropylphenyl), para-(2-methoxy-4-methylphenyl), etc.] and a composition for preventing or treating metabolic diseases, wherein the composition is a potent and selective estrogen-related receptor (ERR) γ inverse agonist with excellent selectivity and since it shows affinity, it can be effectively used for treatment of metabolic diseases. For example, II was prepared and exhibited IC50 of 1.33μM against estrogen-related receptor (ERR) γ. The experimental process involved the reaction of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde(cas: 36640-53-6).Name: 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde

The Article related to preparation pyrazolecarboxamide treatment metabolic disease, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Name: 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On February 4, 2020, Wang, Renxiao; Liu, Hong; Yu, Biao; Li, Yangfeng; Li, Chunpiao; Li, Yan; Zhou, Mi; Li, Qing; Su, Minyi published a patent.Application of 36640-53-6 The title of the patent was Phenyl pyrazole compound, its pharmaceutical composition, preparing method and application. And the patent contained the following:

The invention relates to Ph pyrazole compounds of formula I and II, their preparation and application as Bcl inhibitor. Compounds I and II, wherein Ra is R1(O)n(CH2)m; R1 is C6-14 aryl or substituted C6-14 aryl; m is 0-6; n is 0 or 1; R is H or C1-C4 alkyl; Rb and Rc are independently H, C3-C8 cycloalkyl, C1-C6 alkyl, etc.; their stereoisomers, or pharmaceutically acceptable salts, are claimed. The inventive compound can be applied in preparing the drugs for preventing and/or treating Bcl-related diseases or preparing Bcl inhibitor, with high activity and low toxicity. The experimental process involved the reaction of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde(cas: 36640-53-6).Application of 36640-53-6

The Article related to phenyl pyrazole preparation bcl inhibitor treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Application of 36640-53-6

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On February 24, 1972, Rainer, Georg; Riedel, Richard published a patent.Formula: C20H14N2O The title of the patent was 4-(Hydroxymethyl)- and 4-formyl-1-arylpyrazoles. And the patent contained the following:

Thirty title compounds [I, R = CHO or CH2OH; R1 = (substituted) phenyl, 3-pyridyl, 2-furyl, or 2-naphthyl; R2 = H, F, Cl, Br, Me, or MeO], useful as intermediates for pharmaceutical 4-(carboxymethyl)- or 4-(cyanomethyl)-1-arylpyrazoles, were prepared by reacting R1CMe:NNHC6H4R2-p with DMF and POCl3 via I (R = CH:N+Me2ClO4-) (Ia). Saponifying Ia gave I (R = CHO), which on reduction gave I (R = CH2OH). Thus, POCl3 was stirred 1 hr with DMF and treated with p-ClC6H4CMe:NNHPh 6 hr at 70°. The mixture was treated 5 hr with aqueous NaOH at pH 7 to give 99% I (R = CHO, R1 = C6H4Cl-p, R2 = H) (II). II was treated in EtOH and DMF with NaBH4 1 hr at 20-5° to give 93% I (R = CH2OH, R1 = C6H4Cl-p, R2 = H). The experimental process involved the reaction of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde(cas: 36640-53-6).Formula: C20H14N2O

The Article related to pyrazolecarboxaldehyde, hydroxymethylpyrazole, benzenes pyrazolyl, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Formula: C20H14N2O

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On May 21, 2019, Sun, Liangpeng; Piao, Huri; Xu, Lili published a patent.Recommanded Product: 36640-53-6 The title of the patent was 1,3-Diarylpyrazole PTP1B inhibitor containing carboxyalkyl rhodamine structure and preparation and application thereof. And the patent contained the following:

The invention provides a compound of 1,3-diarylpyrazole PTP1B inhibitor containing carboxyalkyl rhodamine structure as shown in the formula or a pharmaceutically acceptable salt thereof as a novel protein tyrosine phosphatase 1B (PTP1B) inhibitor. Studies show that the inhibitor can effectively inhibit the activity of PTP1B and can be used as an insulin sensitizer for preventing and/or treating diseases related to insulin resistance mediated by PTP1B, particularly type II diabetes and obesity. The invention also provides a preparation method of the inhibitor. The experimental process involved the reaction of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde(cas: 36640-53-6).Recommanded Product: 36640-53-6

The Article related to diarylpyrazole carboxyalkyl rhodamine preparation ptp1b inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Recommanded Product: 36640-53-6

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On July 16, 2009, Blake, James; Gunawardana, Indrani W.; Le Huerou, Yvan; Mohr, Peter J.; Wallace, Eli M.; Wang, Bin published a patent.Computed Properties of 924909-16-0 The title of the patent was Pyrazolopyridine derivatives and their pharmaceutical compositions as CHK1 and CHK2 kinase inhibitors for the treatment of various diseases and preparation thereof. And the patent contained the following:

Title compounds I and II, their pharmaceutical compositions, and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of CHK1 and CHK2 kinases and useful in the treatment of diseases mediated by said kinases. Compounds of formula I [m, n, p independently = 0 or 1; G = (un)substituted Ph when m = 1, or G = absent, alkyl, or (un)substituted Ph when m = 0; R1 = H, alkyl, haloalkyl, etc.; R2 = H, CF3, (un)substituted alkenyl, etc., with the provision that when R1 = H, then R2 = OR14; R14 = alkyl optionally substituted with 1 or more OH; R3, R7, and R8 independently = H or alkyl; R5, R6, and R9 independently = H or Me] and II [Q = CH2 or CH2CH2; R15 and R16 independently = H or alkyl], their pharmaceutical compositions, and their pharmaceutically acceptable salts, are claimed. For example, compound III·2HCl was prepared via amidation of (S)-3-(tert-butoxycarbonyl(isopropyl)amino)-2-(4-chlorophenyl)propanoic acid with 5-phenyl-4-(piperazin-1-yl)-1H-pyrazolo[3,4-b]pyridine dihydrochloride, followed by removal of the BOC protecting group. Select I and II were assayed for CHK1 kinase activity and found to possess IC50 values of <10 μM. The experimental process involved the reaction of 1-(4-Methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-ol(cas: 924909-16-0).Computed Properties of 924909-16-0

The Article related to pyrazolopyridine derivative preparation chk1 chk2 kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Computed Properties of 924909-16-0

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On November 17, 2011, Mulvihill, Mark J.; Steinig, Arno G.; Crew, Andrew Philip; Jin, Meizhong; Kleinberg, Andrew; Li, An-Hu; Wang, Jing published a patent.Category: pyrazoles-derivatives The title of the patent was Preparation of fused bicyclic heterocycles as kinase inhibitors. And the patent contained the following:

Title compounds I [X = H, (C1-3)alkyl, O(C1-3)alkyl, either is optionally substituted with halo or CN; W-V = C-N or N-C; Y1, Y2 = N or CH as long as not more than one of Y1 and Y2 is N; Y3 = NH, CH; Y4 = N, CH; Y5 = N, C as long as not more than one of Y4 and Y5 is N; R3 , R4, R5, R6, R7 = H, alkyl, cyclic compound, O-alkyl, O-cyclic compound, S, SO2, SO, NH2, CONH2, CO2H, acyl, ureido, S-cyclic compound; G1 = H, alkyl, cyclic compound; R17, R18 = H, alkyl, O-alkyl, CONH2, cyclic compound, CO2H, NH2] were prepared and tested in different kinase inhibitory assays. For example, reacting (4-bromo-1-methyl-1H-pyrazol-3-yl)methanol with borane II gave pyrrolo[2,3-b]pyridine III. The compounds are also useful for treating cancers in part by inhibiting different kinases such as MET, RON, or ALK. This abstract is not limiting of the invention. The experimental process involved the reaction of 5-Methoxy-1H-pyrazole(cas: 215610-30-3).Category: pyrazoles-derivatives

The Article related to bicyclic heterocycle fused preparation anticancer kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Category: pyrazoles-derivatives

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On September 20, 2018, Bandiera, Tiziano; Bertozzi, Fabio; Di Fruscia, Paolo; Sorana, Federico; Berti, Francesco; Rodriguez Gimeno, Alejandra; Caci, Emanuela; Ferrera, Loretta; Pedemonte, Nicoletta; Vicente Galietta, Luis Juan published a patent.Category: pyrazoles-derivatives The title of the patent was Preparation of heterocyclic compounds for the treatment of cystic fibrosis. And the patent contained the following:

The invention relates to compounds of formula I or pharmaceutically acceptable salts or solvates thereof; their preparation an use to modulate CFTR protein or ABC protein activities. Compounds of formula I, wherein R1 is C1-6 alkyl, C3-6 cycloalkyl and hydroxy-C1-6 alkyl; Z is CO and SO2; X1, X2, X3 and X4 are independently CR and N; R is H, C1-6 alkyl, aryl, etc.; R2 is H, C1-6 alkyl, OH, CN, etc.; A1 , A2, A3 and A4 are independently O, CO, SO2, etc.; B is (un)substituted aromatic and heteroaromatic; n and m are independently 0, 1, 2; and pharmaceutically acceptable salts and solvates thereof, are claimed. Example compound II was prepared by cyclocondensation of 3-hydrazinobenzoic acid tert-Bu 4-oxo-3-(2,2,2-trifluoroacetyl)piperidine-1-carboxylate to give 3-[5-tert-butoxycarbonyl-3-(trifluoromethyl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]benzoic acid, which underwent amidation with N-methyl-1,3-benzodioxol-5-amine hydrochloride to give II. The invention compounds were evaluated for their CFTR modulatory activity. From the assay, it was determined that compound II exhibited EC50 value of < 1 μM. The experimental process involved the reaction of 3-Methyl-1H-pyrazolo[3,4-b]pyridin-5-amine(cas: 1186608-73-0).Category: pyrazoles-derivatives

The Article related to heterocycle preparation cystic fibrosis cftr abc protein modulator, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Category: pyrazoles-derivatives

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On April 22, 2021, Chen, Yuzhong; Freudenberger, John Herbert; Wright, James published a patent.SDS of cas: 1187582-58-6 The title of the patent was Methods for the preparation of 5-bromo-2-(3-chloropyridin-2-yl)-2H-pyrazole-3-carboxylic acid. And the patent contained the following:

Described herein are novel methods of synthesizing 5-bromo-2-(3-chloro-pyridin-2-yl)-2H-pyrazole-3-carboxylic acid from pyrazole or pyrazole derivatives For example, protecting pyrazole with 3,4-dihydro-2H-pyrazole followed by bromination of the resulting 1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole, deprotecting (5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole containing 3-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole), coupling 3-bromo-1H-pyrazole with 2,3-dichloropyridine, and reacting 2-(3-bromo-1H-pyrazol-1-yl)-3-chloropyridine with CO2 in the presence of TMPMgCl.LiCl solution in THF afforded 5-bromo-2-(3-chloro-pyridin-2-yl)-2H-pyrazole-3-carboxylic acid. General method of preparing compound I [each of R5-R10 = (independently) H and halo; and R13 = an organic acid], starting by halogenation of protected pyrazole II [R14 = (un)substituted carbocycle and heterocycle], was disclosed. The experimental process involved the reaction of 5-Bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole(cas: 1187582-58-6).SDS of cas: 1187582-58-6

The Article related to bromochloropyridinylpyrazolecarboxylic acid preparation intermediate, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.SDS of cas: 1187582-58-6

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On September 11, 2009, Ahrendt, Kateri A.; Buckmelter, Alexandre J.; De Meese, Jason; Grina, Jonas; Hansen, Joshua D.; Laird, Ellen R.; Lunghofer, Paul; Moreno, David; Newhouse, Brad; Ren, Li; Seo, Jeongbeob; Tian, Hongqi; Wenglowsky, Steven Mark; Feng, Bainian; Gunzner, Janet; Malesky, Kim; Mathieu, Simon; Rudolph, Joachim; Wen, Zhaoyang; Young, Wendy B. published a patent.Reference of 3-Methyl-1H-pyrazolo[3,4-b]pyridin-5-amine The title of the patent was N-Pyrazolo[3,4-b]pyridinyl benzamide derivatives as Raf inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. And the patent contained the following:

Compounds of formula I are useful for inhibition of Raf kinases. Methods of using compounds of formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo prevention or treatment of Raf-mediated disorders in mammalian cells, or associated pathol. conditions are disclosed. Compounds of formula I wherein R1 and R2 are independently H, halo, CN, C1-3 alkyl and C1-3 alkoxy; R3 is H, halo and C1-3 alkyl; R4 is C3-5 cycloalkyl, C1-6 alkyl, C2-6 alkenyl, etc.; R5 is H, halo, CN, NH2 and derivatives, etc.; and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by cyclization of 1H-pyrazol-5-amine with 2-bromomalonaldehyde; the resulting 5-bromo-1H-pyrazolo[3,4-b]pyridine underwent alkylation with 2-(trimethylsilyl)ethoxymethyl chloride to give 5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[3,4-b]pyridine, which underwent cross-coupling with tert-Bu carbamate to give tert-Bu 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[3,4-b]pyridin-5-ylcarbamate, which underwent hydrolysis to give 1H-pyrazolo[3,4-b]pyridin-5-amine, which underwent amidation with 2.6-difluoro-3-(propylsulfonamido)benzoic acid to give compound II. All the invention compounds were evaluated for their Raf inhibitory activity. From the assay, it was determined that compound II along with the other example compound exhibited IC50 values of less than 1 μM. The experimental process involved the reaction of 3-Methyl-1H-pyrazolo[3,4-b]pyridin-5-amine(cas: 1186608-73-0).Reference of 3-Methyl-1H-pyrazolo[3,4-b]pyridin-5-amine

The Article related to pyrazolopyridinyl benzamide preparation raf inhibitor treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Reference of 3-Methyl-1H-pyrazolo[3,4-b]pyridin-5-amine

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics